Fennec Pharmaceuticals (FENC) Tops Q2 EPS by 3c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q2 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $17.87 million versus the consensus estimate of $16.39 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Stifel Reiterates Buy Rating on Analog Devices (ADI), Expects Solid Q3 Results
• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• LB Pharmaceuticals Inc (LBRX) Misses Q2 EPS by 93c